Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARCT-2304
- Development stage
- Phase 2
- Lead developer
- Arcturus Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ARCT-2304 is a self-amplifying mRNA (sa-mRNA) vaccine candidate developed by Arcturus Therapeutics for the prevention of Pandemic Influenza A Virus H5N1. The vaccine utilizes Arcturus's proprietary STARR sa-mRNA platform and LUNAR lipid-mediated delivery system. Unlike conventional mRNA vaccines, sa-mRNA is designed to replicate within the cell, potentially allowing for lower dosing levels while maintaining robust immunogenicity. The development of ARCT-2304 is supported by a cost-reimbursement contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for up to $63.2 million, covering preclinical activities through Phase 1 clinical trials. A Phase 1 study in healthy adults is currently ongoing in the United States to evaluate safety, reactogenicity, and immunogenicity.
- Brand names
- LUNAR-H5N1LUNAR-H-5N1LUNAR-H 5N1
- Other names
- LUNAR-H5N1LUNAR-H-5N1LUNAR-H 5N1
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on ARCT-2304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARCT-2304.